Cargando…

Mineralocorticoid receptor antagonists in cardiovascular translational biology

This review examines the role of mineralocorticoid receptor antagonists (MRAs) in cardiovascular biology and the molecular mechanisms involved in mineralocorticoid receptor antagonism. The data discussed suggest that MRAs can play an important role in decreasing the impact of inflammation and fibros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chilton, Robert J., Silva-Cardoso, José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443768/ https://www.ncbi.nlm.nih.gov/pubmed/37614245 http://dx.doi.org/10.1097/XCE.0000000000000289

Ejemplares similares

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
por: Rahman, Asadur, et al.
Publicado: (2023)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives
por: Vizzardi, Enrico, et al.
Publicado: (2014)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Nonsteroidal Mineralocorticoid Receptor Antagonists and Protection Against Cardiovascular Disease in Patients with Diabetes Mellitus
por: Shimabukuro, Michio
Publicado: (2023)

Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review
por: Mai, Xurong, et al.
Publicado: (2022)

Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology
por: Cannavo, Alessandro, et al.
Publicado: (2018)

Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
por: Gou, Wen-Jun, et al.
Publicado: (2022)

Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists
por: Pérez-Gordillo, Felipe Luis, et al.
Publicado: (2023)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
por: Duran, Jason M., et al.
Publicado: (2020)

Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists
por: Yoshida, Yuichi, et al.
Publicado: (2021)

Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats
por: Yamamoto, Kanako, et al.
Publicado: (2018)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology
por: Viengchareun, Say, et al.
Publicado: (2007)

Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction
por: Chang, Wei-Ting, et al.
Publicado: (2022)

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
por: Folkerts, Kerstin, et al.
Publicado: (2022)

Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
por: Berbenetz, Nicolas M., et al.
Publicado: (2016)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
por: Henrysson, Josefin, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges
por: Fujii, Wataru, et al.
Publicado: (2023)

Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging
por: Gorini, Stefania, et al.
Publicado: (2019)

Posttranslational Modifications of the Mineralocorticoid Receptor and Cardiovascular Aging
por: Gadasheva, Yekatarina, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!
por: Maiolino, Giuseppe, et al.
Publicado: (2015)

SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
por: Tezuka, Yuta, et al.
Publicado: (2020)

Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
por: Wu, Yichuan, et al.
Publicado: (2022)

Cardiovascular Disease in Obstructive Sleep Apnea: Putative Contributions of Mineralocorticoid Receptors
por: Badran, Mohammad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_knqq3heavbdfcnakk017pskp3f